GYRE · Gyre Therapeutics, Inc.
Market Cap
$714.78M
Shares
111.51M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-09-01 | — | |
| 8-K | 2026-08-26 | — | |
| 8-K | 2026-08-07 | — | |
| 10-Q | 2026-08-07 | 2026-06-30 | |
| 8-K | 2026-07-16 | 2026-07-10 | |
| 8-K/A | 2026-07-15 | 2026-05-04 | |
| 8-K | 2026-06-16 | 2026-06-10 | |
| 8-K | 2026-06-02 | 2026-06-01 | |
| 8-K | 2026-05-14 | — | |
| 8-K | 2026-05-12 | — | |
| 10-Q | 2026-05-08 | 2026-03-31 | |
| 8-K | 2026-05-07 | — | |
| 8-K | 2026-05-04 | — | |
| DEF 14A | 2026-04-27 | 2026-06-10 | |
| 8-K/A | 2026-04-17 | 2026-03-02 | |
| 8-K | 2026-03-23 | 2026-03-22 | |
| 10-K | 2026-03-13 | 2025-12-31 | |
| 8-K | 2026-03-12 | — | |
| 8-K | 2026-03-12 | 2026-03-10 | |
| 8-K | 2026-03-02 | — | |
| 8-K | 2026-01-05 | — | |
| 8-K | 2025-11-07 | — | |
| 10-Q | 2025-11-07 | 2025-09-30 | |
| 8-K | 2025-09-10 | — | |
| 8-K | 2025-08-22 | 2025-08-18 | |
| 10-Q | 2025-08-11 | 2025-06-30 | |
| 8-K | 2025-08-11 | 2025-08-05 | |
| 8-K | 2025-06-06 | 2025-06-04 | |
| 8-K | 2025-05-23 | 2025-05-22 | |
| 8-K | 2025-05-22 | — | |
| 10-Q | 2025-05-09 | 2025-03-31 | |
| 8-K | 2025-05-09 | — | |
| 8-K | 2025-04-28 | — | |
| DEF 14A | 2025-04-21 | 2025-06-04 | |
| 8-K | 2025-03-17 | — | |
| 10-K | 2025-03-17 | 2024-12-31 | |
| 8-K | 2025-02-18 | 2025-02-14 | |
| 8-K | 2025-01-06 | 2024-12-31 | |
| 8-K | 2024-11-27 | — | |
| 10-Q | 2024-11-13 | 2024-09-30 | |
| 8-K | 2024-11-13 | — | |
| 8-K | 2024-08-13 | — | |
| 10-Q | 2024-08-13 | 2024-06-30 | |
| 8-K | 2024-08-08 | 2024-08-06 | |
| 8-K | 2024-07-05 | 2024-06-28 | |
| 8-K | 2024-06-17 | 2024-06-12 | |
| 8-K | 2024-05-30 | — | |
| 10-Q | 2024-05-13 | 2024-03-31 | |
| 8-K | 2024-05-09 | — | |
| 8-K | 2024-05-08 | 2024-05-07 |
Showing 1–50 of 156 filings
Key facts
CIK
1124105
CUSIP
403783103
13F (30d)
45 filings
45 filers
Visit website
Investor relations